Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Mozobil | Plerixafor | Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma | Do not list | Complete | ||
Eliquis | Apixaban | Venous thromboembolic events, prevention | List with clinical criteria and/or conditions | Complete | ||
Saphris | Asenapine | Schizophrenia | Do not list | Complete | ||
Effient | Prasugrel | Acute coronary syndrome | Do not list | Complete | ||
Saphris | Asenapine | Bipolar I disorder | List with clinical criteria and/or conditions | Complete | ||
Zelboraf | Vemurafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Yervoy | Ipilimumab | Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
ASMANEX | Mometasone furoate | Asthma | List | Complete | ||
Sutent | Sunitinib malate | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
Gelnique | Oxybutynin Chloride Gel | Overactive bladder | Do not list | Complete |